Masoud S, et al. - Experts herein assessed ofatumumab (a fully humanized anti-CD20 mAb) as an alternative B cell–depleting agent in patients with SLE who were rituximab-intolerant due to severe infusion reactions. For B cell–depletion therapy in this pre-treated cohort with long-standing SLE, ofatumumab was shown to be a well-tolerated, safe and effective alternative to rituximab.